Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Acetylcysteine - Zambon

Next Previous
Drug Profile

Acetylcysteine - Zambon

Alternative Names: Fluimucil; Flumil; N-acetylcysteine - Zambon; NAC - Zambon; NSC 111180; Rinofluimucil

Latest Information Update: 30 Jun 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Zambon Company SpA
  • Developer Elder Pharmaceuticals; Inpharzam Ricerche S.A.; Sermmitr; Zambon Company SpA
  • Class Anti-inflammatories; Antibronchitics; Antidotes; Expectorants; Reducing agents; Small molecules; Sulfur amino acids
  • Mechanism of Action Antioxidants; Free radical inhibitors; Glutamate receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pulmonary fibrosis
  • New Molecular Entity No

Highest Development Phases

  • Marketed Chronic obstructive pulmonary disease; Common cold; Poisoning; Respiratory tract disorders
  • Discontinued HIV infections; Pulmonary fibrosis; Renal failure

Most Recent Events

  • 24 Jun 2025 Zambon approves acetylcysteine for Respiratory tract disorders in China (IV)
  • 24 Jun 2025 Zambon launches acetylcysteine for Respiratory tract disorders in China (IV)
  • 05 Feb 2021 Zambon completes a phase III trial for Respiratory tract disorers in China (IV, Infusion) (NCT03843541)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top